Artiva Biotherapeutics, Inc.

ARTV Healthcare Biotechnology

Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.85 0.21 −3.47%
Market cap
$296.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
n/a
Altman Z
1.27
Beneish M
−22.63
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
11.65 8.61 8.16 24.16
Net Debt/EBITDA
5.53 5.08 3.65 13.34
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.81) (0.62) (0.86) (0.53)
Book value per Share
5.28 4.50 3.56 8.82
Free Cash Flow
(19.80) (15.15) (21.19) (20.77)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates